ERBB2 and breast carcinoma: While Trilaciclib is specifically indicated to mitigate chemotherapy-induced myelosuppression, the remaining four agents are predominantly utilized in combination with endocrine therapies for HR+/HER2- breast cancer, reflecting their established role as first-line treatments in this molecular subtype.